Close Menu

NEW YORK – NeoGenomics announced Tuesday a 51 percent year-over-year uptick in its third quarter revenues, with growth in both its clinical services and pharma services businesses. 

For the three months ended Sept. 30, total revenues reached $104.7 million, up from $69.1 million in Q3 2018. It beat the analysts' average estimate of $99.1 million.

Organic revenue growth was greater than 20 percent, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.